Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer Review

   


Authors: Alberto, M.; Yim, A.; Papa, N.; Siva, S.; Ischia, J.; Touijer, K.; Eastham, J. A.; Bolton, D.; Perera, M.
Review Title: Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
Abstract: Oligometastatic prostate cancer (OMPC) has been proposed as an intermediary state between localised disease and widespread metastases, with varying definitions including 1, 3, or ≤5 visceral or bone metastasis. Traditional definitions of OMPC are based on staging with conventional imaging, such as computerised tomography (CT) and whole-body bone scan (WBBS). Novel imaging modalities such as prostate-specific membrane antigen positron emission tomography (PSMA PET) have improved diagnostic utility in detecting early metastatic prostate cancer (PC) metastases compared with conventional imaging. Specifically, meta-analytical data suggest that PSMA PET is sensitive in detecting oligometastatic disease in patients with biochemical recurrence (BCR) post-radical treatment of PC. Recent trials have evaluated PSMA PET-guided metastases-directed therapy (MDT) in oligometastatic recurrent disease, typically with salvage surgery or radiotherapy (RT). To date, these preliminary studies demonstrate promising results, potentially delaying the need for systemic therapy. We aim to report a comprehensive, multidisciplinary review of PSMA-guided MDT in OMPC. In this review, we highlight the utility of PMSA PET in biochemically recurrent disease and impact of PSMA PET on the definition of oligometastatic disease and outline data pertaining to PSMA-guided MDT. Copyright © 2022 Alberto, Yim, Papa, Siva, Ischia, Touijer, Eastham, Bolton and Perera.
Keywords: treatment outcome; overall survival; review; cancer recurrence; bone metastasis; cancer radiotherapy; disease free survival; cancer staging; nuclear magnetic resonance imaging; positron emission tomography; lymph node metastasis; lymph node dissection; cytoreductive surgery; metastasis; computer assisted tomography; tumor volume; prostate cancer; gleason score; prostate specific membrane antigen; prostatectomy; fluorodeoxyglucose f 18; medronate technetium tc 99m; visceral metastasis; prostate adenocarcinoma; stereotactic body radiation therapy; indium 111; androgen deprivation therapy; biochemical recurrence; bone scintiscanning; metastatic disease; recurrence free survival; oligometastasis; human; male; oligometastatic; positron emission tomography-computed tomography; local progression free survival; psma pet; gallium gozetotide ga 68; metastastases directed therapy; vipivotide tetraxetan lutetium lu 177
Journal Title: Frontiers in Oncology
Volume: 12
ISSN: 2234-943X
Publisher: Frontiers Media S.A.  
Date Published: 2022-08-18
Start Page: 929444
Language: English
DOI: 10.3389/fonc.2022.929444
PROVIDER: scopus
PMCID: PMC9433573
PUBMED: 36059632
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137532961&doi=10.3389%2ffonc.2022.929444&partnerID=40&md5=ad267be2b831263d51162e17b5e5bed9
Notes: Review -- Export Date: 3 October 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Karim Abdelkrim Touijer
    257 Touijer
  2. James Eastham
    537 Eastham
  3. Marlon Lakmal Perera
    24 Perera
Related MSK Work